Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Creatine may increase DHT levels, potentially causing symptoms like acne, oily hair, and hair shedding. Users report mixed experiences, with some avoiding creatine due to hair loss concerns and others seeing no impact.

A user saw no results from using minoxidil and microneedling for 1.5 years and is considering trying tretinoin. They are seeking others' experiences with tretinoin for hair loss.

The post discusses using oral Minoxidil and Dutasteride for hair loss. Minoxidil improved hair growth with mild hypertrichosis, while Dutasteride caused severe acne, cognitive issues, and mild anxiety, leading the user to prefer Finasteride.

A 21-year-old started using topical minoxidil, finasteride (0.7 mg), and microneedling for hair loss treatment after beginning to bald at 18. They are eager to see the results after two months of treatment.

The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation criticizes the negative attitude towards those concerned about side effects from hair loss treatments like finasteride and minoxidil, or who prefer natural remedies. Specific treatments discussed include finasteride, minoxidil, rosemary oil, and RU58841, with an agreement that finasteride and minoxidil are proven effective.

The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The conversation is about a user experiencing worsening hair loss despite using minoxidil for four months, with suggestions to add finasteride or dutasteride for better results. Some users recommend consulting a dermatologist and considering other treatments like steroids if it's alopecia areata.

Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.

The user switched from topical to oral finasteride and minoxidil pills for hair loss but hasn't seen results after 4 months. Others suggest it may take longer to see improvements and recommend considering additional treatments.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

The user is questioning if they are experiencing hair regrowth after using topical Minoxidil for 4-5 months, noting increased body hair but uncertain head hair changes. Other users suggest the appearance is due to a natural cowlick rather than balding.

The conversation discusses hair shedding while using finasteride and topical minoxidil, with users sharing their experiences of losing 30-100 hairs daily in the shower. One user considers switching to dutasteride due to consistent shedding.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

A user experienced hair shedding after six months of using topical minoxidil and is considering adding finasteride to their routine. Many suggest that minoxidil alone is insufficient for stopping hair loss and recommend combining it with finasteride or dutasteride for better results.

The user started using dutasteride 7 months ago and added RU58841, finasteride, and minoxidil 2 months ago. Opinions on progress vary, with some noting shedding and dandruff, while others suggest natural scalp care and patience for results.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

A 24-year-old shared their 6-month hair regrowth progress using 1mg oral finasteride, 1ml 5% minoxidil, and 1% topical finasteride daily, noting initial side effects that subsided. They addressed vitamin D, B12 deficiencies, and thyroid issues, expressing satisfaction with the results and encouraging patience with the treatment.

The user is considering using tretinoin with topical finasteride due to poor absorption and side effects from oral finasteride. They are also contemplating switching to topical dutasteride, while others suggest trying oral minoxidil or lower oral doses.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

A 27-year-old shared progress 6 months after a hair transplant of 4500 grafts, using finasteride and minoxidil. The procedure was done at Vera Clinic in Istanbul, costing 3000 Euros, and the user is pleased with the results.